Karin Jooss
Chief Tech/Sci/R&D Officer chez GRITSTONE BIO, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019.
She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021.
Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016.
Dr. Jooss holds a doctorate degree from Philipps University of Marburg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0,40% | 01/02/2024 | 395 204 ( 0,40% ) | 1 M $ | 31/03/2024 |
FATE THERAPEUTICS, INC.
0,01% | 06/06/2023 | 9 848 ( 0,01% ) | 72 284 $ | 31/03/2024 |
Postes actifs de Karin Jooss
| Sociétés | Poste | Début |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 13/04/2016 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 14/03/2019 |
Anciens postes connus de Karin Jooss
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 01/04/2009 |
Formation de Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
